Clinical and pharmacoeconomic aspects of the use of prolonged colony-stimulating factors

A. A. Rumyantsev
2022 Medical Council  
Febrile neutropenia is one of the frequent complications of systemic antitumor therapy, characterized by high rates of patient mortality, mortality is particularly high in patients with pre-existing cardiovascular disease, renal disease, as well as in the presence of anemia. In addition, the development of febrile neutropenia is associated with a decrease in the dose intensity of chemotherapy, which also has an adverse effect on the long-term results of treatment of patients with a number of
more » ... ignant tumors. This dictates the need for widespread use of preventive measures aimed at minimizing the risk of FN in cancer patients receiving cytotoxic chemotherapy. Numerous studies have shown that prophylactic use of granulocyte colony-stimulating factors can significantly reduce the duration of profound neutropenia, the incidence of FN and - most importantly - related mortality. This article is devoted to a review of modern approaches to the use of granulocyte colony-stimulating factors (G-CSF) in the context of the current system of cancer care financing - clinical and statistical groups (CSGs) on the territory of the Russian Federation. Various aspects of the use of drugs of this class to prevent febrile neutropenia in the context of its primary and secondary prevention, the rules of G-CSF use, current data on the effectiveness and feasibility of use in different clinical scenarios are considered in detail. The advantages of modern long-acting dosage forms of G-CSF and their place in modern clinical practice are considered.
doi:10.21518/2079-701x-2022-16-22-112-118 fatcat:zo6jgrmbavcpjis7zfdemxbcye